Drugs / anti-MART-1 F5 cells
anti-MART-1 F5 cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00612222 | Jan 2008 → Mar 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-MART-1 F5 cells | “special cells called anti-MART-1 F5 cells that are designed to destroy the patient's tumor” NCT00612222 ↗ |
| Known as | anti-MART-1 F5 TCR transduced peripheral blood lymphocytes | “The anti-MART-1 F5 TCR transduced peripheral blood lymphocytes (PBL) could efficiently kill HLA-A 0201 positive tumors.” NCT00612222 ↗ |
| Known as | anti-MART-1 F5 TCR-gene engineered lymphocytes | “infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization” NCT00612222 ↗ |
| Action | Deplete | “special cells called anti-MART-1 F5 cells that are designed to destroy the patient's tumor” NCT00612222 ↗ |
| Route | Intravenous | “The anti-MART-1 F5 cells are given as an infusion through a vein” NCT00612222 ↗ |